Pathstone Family Office’s Corcept Therapeutics CORT Stock Holding History

Pathstone Family Office’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$271K	Buy	+9,933	New	+$287K	﹤0.01%	1361

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Pathstone Family Office's CORT Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Corcept Therapeutics (CORT) in Q3 2023: 9,933 shares worth $271K. The stake represents ﹤0.01% of the portfolio and ranks #1361 among its holdings.

246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

Pathstone Family Office held 9,933 shares of Corcept Therapeutics worth $271K as of Q3 2023.
Corcept Therapeutics was a new Pathstone Family Office position in Q3 2023.
Corcept Therapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1361 holding.
246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.